WO2010144797A3 - Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations - Google Patents

Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations Download PDF

Info

Publication number
WO2010144797A3
WO2010144797A3 PCT/US2010/038309 US2010038309W WO2010144797A3 WO 2010144797 A3 WO2010144797 A3 WO 2010144797A3 US 2010038309 W US2010038309 W US 2010038309W WO 2010144797 A3 WO2010144797 A3 WO 2010144797A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
influenza virus
present
vaccine composition
relates
Prior art date
Application number
PCT/US2010/038309
Other languages
English (en)
Other versions
WO2010144797A2 (fr
Inventor
Yichen Lu
Neal Touzjian
Shu Li
Original Assignee
Vaccine Technologies, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccine Technologies, Incorporated filed Critical Vaccine Technologies, Incorporated
Publication of WO2010144797A2 publication Critical patent/WO2010144797A2/fr
Publication of WO2010144797A3 publication Critical patent/WO2010144797A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte d'une manière générale sur des compositions de vaccin contre la grippe et sur des procédés d'utilisation. Un aspect de la présente invention porte sur une composition de vaccin comprenant un support pharmaceutiquement acceptable et une préparation d'antigène, la préparation d'antigène comprenant un polypeptide de nucléoprotéine de virus de la grippe (NP) et facultativement une protéine de matrice du virus de la grippe (M). Un autre aspect de la présente invention porte sur une composition de vaccin contre le virus de la grippe et sur des procédés d'utilisation, comprenant une protéine NP et/ou M de virus de la grippe et un polypeptide de facteur létal de Bacillus anthracis (LF), tel qu'un polypeptide LFn, une partie N-terminale du polypeptide LF. Dans certains modes de réalisation, le polypeptide LF peut être fusionné ou sinon associé au polypeptide NP ou M; ou en variante, ou de façon additionnelle, associé à l'un quelconque ou à la totalité des polypeptides antigéniques de virus de la grippe (par exemple, HA, NA, etc.) dans la composition de vaccin.
PCT/US2010/038309 2009-06-12 2010-06-11 Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations WO2010144797A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18642209P 2009-06-12 2009-06-12
US61/186,422 2009-06-12

Publications (2)

Publication Number Publication Date
WO2010144797A2 WO2010144797A2 (fr) 2010-12-16
WO2010144797A3 true WO2010144797A3 (fr) 2011-06-30

Family

ID=43038208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/038309 WO2010144797A2 (fr) 2009-06-12 2010-06-11 Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2010144797A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013001514A2 (pt) * 2010-07-23 2016-06-07 Erasmus University Rotterdam Medical Ct vacina para influenza
KR102633621B1 (ko) 2017-09-01 2024-02-05 벤 바이오사이언시스 코포레이션 진단 및 치료 모니터링용 바이오마커로서의 당펩티드의 식별 및 용도
MX2019014943A (es) 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
CN117844643B (zh) * 2024-03-06 2024-06-07 天津中逸安健生物科技有限公司 一种基于转基因小球藻制备的重组流感疫苗的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003145A1 (fr) * 1994-07-26 1996-02-08 Connaught Laboratories, Inc. Conjugues de sous-unites de virus de la grippe

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
US4057626A (en) 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
NL7704348A (nl) 1977-04-21 1978-10-24 Philips Nv Werkwijze voor het bereiden van een geattenueer- de transmissible gastroenteritis(tge)-virusstam voor toepassing in levende vaccins.
US4318903A (en) 1978-07-12 1982-03-09 Smithkline-Rit Live influenza virus vaccine and the preparation thereof
JPS55147227A (en) 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US4278662A (en) 1979-10-16 1981-07-14 Smith Kline - Rit Attenuated influenza type A virus vaccine
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4552758A (en) 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4552757A (en) 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Use in an animal host and precursors for vaccines utilizing avian-human reassortants to combat influenza A virus
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4783411A (en) 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5179007A (en) 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
US5149531A (en) 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
US6022726A (en) 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5591631A (en) 1993-02-12 1997-01-07 The United States Of America As Represented By The Department Of Health And Human Services Anthrax toxin fusion proteins, nucleic acid encoding same
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
US5976552A (en) 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU7838194A (en) 1993-09-20 1995-04-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for generating influenza a viruses bearing attenuating mutations in internal protein genes
AU1377395A (en) 1993-12-23 1995-07-10 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5646033A (en) 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
GB9809666D0 (en) 1998-05-06 1998-07-01 Isis Innovation Modified viruses
AU771110B2 (en) 1998-06-12 2004-03-11 Mount Sinai School Of Medicine Of The City University Of New York, The Novel methods and interferon deficient substrates for the propagation of viruses
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
CN1451038A (zh) 1999-07-30 2003-10-22 埃西斯创新有限公司 可用作疫苗的减毒流感病毒
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
ATE384786T1 (de) 1999-12-20 2008-02-15 Agricultural Research Council Verfahren zur inaktivierung von mikroorganismen
AU2001238478C1 (en) 2000-02-15 2006-11-09 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
WO2001083794A2 (fr) 2000-04-28 2001-11-08 St. Jude Children's Research Hospital Systeme de transfection d'adn servant a generer des virus de la grippe infectieuse
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
US6803041B2 (en) 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
CA2442020C (fr) 2001-03-28 2017-03-14 President And Fellows Of Harvard College Methodes de distribution de proteines exogenes au cytosol et leurs utilisations
GB2393122B (en) 2001-06-08 2005-12-28 Avant Immunotherapeutics Inc Improved vaccination against anthrax
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1597400B8 (fr) 2003-02-25 2013-10-09 MedImmune, LLC Procedes de production de compositions vaccinales contre la grippe
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
WO2005012535A2 (fr) 2003-08-01 2005-02-10 Phytovation B.V. Procede d'elaboration de virus vivants attenues, et utilisation de particules virales ainsi obtenues
DE602004027537D1 (fr) 2003-12-23 2010-07-15 Medimmune Inc
AU2006248725A1 (en) 2005-05-19 2006-11-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising B-subunit of E. coli heat toxin and an atigen and an adjuvant
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
US8124397B2 (en) 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
WO2007022425A2 (fr) 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Vaccin a sous-unites recombinees du virus de la grippe
CA2669290A1 (fr) 2005-11-14 2008-04-24 Leslie W. Baillie Vaccins oraux a base de salmonelle contre l'anthrax
GB0524408D0 (en) 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
WO2007066334A1 (fr) 2005-12-06 2007-06-14 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Vaccin ameliore contre la grippe
EP1984022A2 (fr) 2006-01-17 2008-10-29 CREATOGEN Laboratories GmbH Vaccin anti-grippal
WO2007100584A2 (fr) 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents antiviraux et vaccins antigrippaux
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003145A1 (fr) * 1994-07-26 1996-02-08 Connaught Laboratories, Inc. Conjugues de sous-unites de virus de la grippe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COX M M J ET AL: "FluBlok, a next generation influenza vaccine manufactured in insect cells", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 37, no. 3, 1 June 2009 (2009-06-01), pages 182 - 189, XP026136313, ISSN: 1045-1056, [retrieved on 20090317], DOI: DOI:10.1016/J.BIOLOGICALS.2009.02.014 *
O'HAGAN DEREK T ET AL: "MF59: A safe and potent oil in water emulsion adjuvant or influenza vaccines, which induces enhanced protection against virus challenge", 1 January 2008, INFLUENZA VACCINES FOR THE FUTURE (BOOK SERIES: BIRKHÄUSER ADVANCES IN INFECTIOUS DISEASES), BIRKHÄUSER VERLAG AG, PAGE(S) 221 - 244, ISBN: 978-3-7643-8370-1, XP009135959 *

Also Published As

Publication number Publication date
WO2010144797A2 (fr) 2010-12-16

Similar Documents

Publication Publication Date Title
WO2009026397A3 (fr) Vaccins antigrippaux prophylactiques et thérapeutiques, antigènes, compositions et procédés
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
WO2007066334A9 (fr) Vaccin ameliore contre la grippe
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
WO2010115133A8 (fr) Vaccins aviaires transportés par le virus de la maladie de newcastle
WO2007011904A3 (fr) Vaccins recombinants contre la grippe
EP4241785A3 (fr) Vaccins contre le virus de la grippe et leurs utilisations
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
BR112013008700B8 (pt) Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
WO2012024632A3 (fr) Vaccins à nanovecteurs synthétiques contenant des peptides obtenus ou issus de la protéine m2e du virus humain de la grippe a
WO2007095320A3 (fr) Antigènes du papillomavirus humain, compositions de vaccin et méthodes
WO2011103453A3 (fr) Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
WO2009155489A3 (fr) Compositions et procédés pour le traitement de la grippe
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
WO2007047831A3 (fr) Particules fonctionnelles semblables aux virus de la grippe (vlp)
WO2009016639A3 (fr) Vaccins contre la grippe à multiples épitopes multimères
AU2013367751A8 (en) Nasal influenza vaccine composition
WO2007147529A3 (fr) Vaccin viral recombinant
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
IL227947A0 (en) Preparations containing antibodies that bind to the glycoprotein hemagglutinin a and the extracellular domain of the polypeptide to the transverse domain of matrix 2 (e2m) from influenza virus origin and their uses
WO2008054535A3 (fr) Nouveaux vaccins contre l'influenza m2
EP3156070A3 (fr) Vaccins du virus de l'herpès vectorisé par le virus de la maladie de newcastle
WO2011106607A3 (fr) Vaccins à virus fractionné pour les herpesvirus et procédés d'utilisation
WO2008103819A3 (fr) Pseudo-particules virales (vlp) chimériques de la maladie de newcastle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10724974

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10724974

Country of ref document: EP

Kind code of ref document: A2